| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Azido-PEG5-CH2CO2H does not have a specific pharmacological target. As a PEG-based linker, it is not designed to have intrinsic biological activity. Instead, it is a chemical tool used for the conjugation of different molecular entities. The azide group enables copper-catalyzed azide-alkyne cycloaddition (CuAAC) or strain-promoted alkyne-azide cycloaddition (SPAAC) reactions. The terminal carboxylic acid can react with primary amine groups to form stable amide bonds.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [1].
Azido-PEG5-CH2CO2H is used as a chemical reagent for the synthesis of ADCs and PROTAC molecules. Its biological activity is not directly assessed, as it is a linker molecule. The compound's in vitro utility lies in its ability to serve as a building block for the construction of more complex molecules with specific biological activities. The hydrophilic PEG spacer increases solubility in aqueous media. |
| ln Vivo |
In vivo data are not applicable for Azido-PEG5-CH2CO2H, as it is a chemical linker and not a pharmacologically active compound. Its use is limited to chemical synthesis and bioconjugation. The compound is not intended for in vivo administration.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for Azido-PEG5-CH2CO2H, as it is a chemical linker and not a pharmacologically active compound. The compound does not have a specific biological target. Its activity is limited to its chemical reactivity as a building block for bioconjugation.
|
| Cell Assay |
Cellular assays are not typically performed for Azido-PEG5-CH2CO2H, as it is a chemical linker and not a pharmacologically active compound. Its use is limited to chemical synthesis. The compound's biological activity, if any, would be related to the final ADC or PROTAC molecule that incorporates this linker, rather than the linker itself.
|
| Animal Protocol |
In vivo animal studies are not applicable for Azido-PEG5-CH2CO2H, as it is a chemical linker and not a pharmacologically active compound. It is not intended for in vivo administration. The compound is used exclusively for chemical synthesis and bioconjugation in research settings.
|
| ADME/Pharmacokinetics |
Azido-PEG5-CH2CO2H has a molecular weight of 321.33 and a molecular formula of C12H23N3O7. It is soluble in DMSO and other organic solvents. The compound is stable when stored as a powder at -20°C. However, detailed pharmacokinetic parameters are not applicable, as the compound is not a drug and is not intended for in vivo administration.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data are not applicable for Azido-PEG5-CH2CO2H, as it is a chemical linker and not a pharmacologically active compound intended for human consumption. It is classified as a research-use-only chemical. Specific toxicological data are not reported in the available literature.
|
| References | |
| Additional Infomation |
Azido-PEG5-CH2CO2H is a research-grade chemical and a PEG-based ADC and PROTAC linker. It is not a drug and is not approved for clinical use. Its primary applications are in the synthesis of antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs) in chemical biology and drug discovery research. The azide group enables click chemistry conjugation, and the carboxylic acid group enables amide bond formation.
|
| Molecular Formula |
C12H23N3O7
|
|---|---|
| Molecular Weight |
321.32692360878
|
| Exact Mass |
321.153
|
| CAS # |
217180-81-9
|
| PubChem CID |
99129378
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-1.81
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
22
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(CCOCCOCC(=O)O)CCOCCOCCN=[N+]=[N-]
|
| InChi Key |
CEACGPKHPWXRQF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H23N3O7/c13-15-14-1-2-18-3-4-19-5-6-20-7-8-21-9-10-22-11-12(16)17/h1-11H2,(H,16,17)
|
| Chemical Name |
2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~311.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1121 mL | 15.5603 mL | 31.1207 mL | |
| 5 mM | 0.6224 mL | 3.1121 mL | 6.2241 mL | |
| 10 mM | 0.3112 mL | 1.5560 mL | 3.1121 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
